Abstract Recipients of renal transplant are at increased risk of developing various malignancies, especially post-transplant lymphoproliferative disorder (PTLD) and skin cancers. Neuroendocrine tumours (NET) of the gastrointestinal tract have not been reported in this setting. Here we describe the case of a 75-year-old male who had undergone renal transplant 8 years back and now presented with significant weight loss and backache, clinically suspected as PTLD.
Introduction
Renal transplant recipients are prone to develop malignancies as a long-term complication. Skin malignancies and posttransplant lymphoproliferative disorder (PTLD) are the most common malignancy in renal transplant recipients [1] . PTLD is often extranodal and presents as non-specific symptoms depending upon the organ involved (liver, gastrointestinal tract and lung). 
Case Report
A 75-year-old male presented with loss of appetite, weight loss and low backache for 2 months. The patient had a past history of renal transplant 8 years ago for end-stage renal disease, secondary to obstructive uropathy. Since then he has been on a triple regimen of cyclosporine, azathioprine and prednisolone. The patient was well built with a height of 180 cm and weighed 68 kg, but reported weighing 85 kg 3 months earlier. He was non-diabetic, euthyroid and normotensive. At physical examination, mild pallor of the conjunctiva and hepatomegaly was seen. Laboratory workup showed haemoglobin of 8.5 gm%, total leukocyte count of 8,400/ml and platelet count of 160,000/ml. Liver and renal function tests were normal. Ultrasonography of the abdomen revealed multiple hypoechoic lesions involving both lobes of the liver. Against the background of renal transplant, the differential diagnosis of PTLD and hepatocellular carcinoma was considered. The virology profile was negative for HbsAg, anti-HCV and HIV −1 and 2. α-Fetoprotien was found to be 0.91 ng/ml. Liver biopsy was attempted, but the tissue yield was inadequate for forming an opinion. Given the suspicion of PTLD, 18 F-FDG PET-CT was carried out for noninvasive assessment of liver lesions and to look for any extrahepatic spread. PET-CT imaging revealed multiple hypodense lesions in both lobes of the liver with increased 18 F-FDG uptake (SUVmax=2.9) at the periphery of the lesions. A nodular 18 F-FDG-avid lesion was also noted in the rectum (SUVmax=5.4) (Fig. 1) . A repeat liver biopsy was done from the periphery of a hepatic lesion. Histopathological examination (HPE) revealed metastatic poorly differentiated NET, positive for synaptophysin and chromogranin A on immunohistochemistry, and a Ki-67 index of ∼20 % (Fig. 2) . Urinary 5-hydroxyindoleacetic acid was normal (0.68 mg%) and serum chromogranin A was elevated (167.69 ng/ml). Given the NET histology, the patient underwent 68 Ga-DOTANOC PET-CT, which showed the nodular 68 Ga-DOTANOC-avid primary lesion in the rectum (SUVmax=6.3) along with multiple large hypodense metastatic lesions in both lobes of the liver with intense 68 Ga-DOTANOC uptake (SUVmax = 9.6) (Fig. 3) . The rectal lesion was biopsied and turned out to be primary NET. In view of 68 Ga-DOTANOC-avid metastatic disease, the patient was put on a 30 mg monthly dose of octreotide acetate and is being followed up 3 monthly.
Discussion
Transplant recipients are at increased risk of malignancies, the most common being skin cancers and lymphomas. Merkel cell carcinoma, a type of neuroendocrine malignancy of the skin, has been described as a complication after renal transplant [1] . However, so far, gastrointestinal NET has not been described after renal transplantation. On the contrary, PTLD is a known complication of renal transplantation. The patient often presents early after transplantion, and the features are non-specific, such as fever, weight loss, lymphadenopathy, hepatomegaly or even intestinal obstruction [2, 3] . With early diagnosis and effective chemotherapy, and withholding immunosuppressants, a favourable outcome may be achieved. Blaes et al. have shown 18 F-FDG PET-CT to be an effective tool for the assessment of PTLD [4] . In the present case, against the background of renal transplant with continued immunosuppression, the clinical picture raised the suspicion of PTLD. In view of the nonconclusive first liver biopsy and high index of clinical suspicion, the patient was sent for 18 F-FDG PET-CT, which was positive and demonstrated the previously unknown primary rectal tumour.
Usually, gastrointestinal NET presents with features of increased biogenic amines and polypeptides, features distinct from PTLD. They presents with flushing, diarrhoea and other features of excessive amines, mostly serotonin, whereas most of the pancreatic NETs are nonsecretory. Gastrointestinal NET is usually located in the rectum and jejuno-ileal region [5] . Management of these disease entities is quite distinct. NET can be diagnosed and staged accurately with 68 Ga-DOTANOC PET-CT [6] . 18 F-FDG PET has also been shown to have prognostic value, especially in high-grade NET [7] . In our case both Ga-DOTANOC PET-CT does not rule out PTLD. Therefore, the final diagnosis was based on HPE.
In the present case, 18 F-FDG PET-CT was positive for both rectal and liver lesions, raising the possibility of PTLD. However, the biopsy report indicated be poorly differentiated NET and the lesions were later also found to be positive on 68 Ga-DOTANOC PET-CT. The occurrence of NET in our case in the background of a renal transplant could be a coincidental finding, but was still an unusual scenario. Because of Informed consent was obtained from the patient for being included in the study. Additional informed consent was obtained from the patient for whom identifying information is included in this article.
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